Cushing’s syndrome screening with the 1-mg dexamethasone suppression test in metabolically healthy and unhealthy obesity phenotypes
Authors' conclusion
While the 1 mg DST is a practical screening test for CS with high specificity in obesity, the number of CS cases detected remains relatively low. Therefore, it may be more reasonable and applicable to screen patients with MUO phenotype rather than all individuals with obesity.
Study context
- Population
- Patients with obesity screened for Cushing's syndrome (CS) with the 1 mg dexamethasone suppression test (DST)
- Participants
- 1,008 patients
- Exposure
- MUO vs metabolically healthy obesity (MHO) phenotype
- MUOn = 779
- Outcome
- Prevalence of CS in the population with obesity
Main finding
As reported in the abstract
Prevalence of CS
Hypercortisolism definitively diagnosed
2 patients
Overall prevalence of CS
0.2%
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Cortisol levels after 1 mg DSTSignificantly higher with MUO | P = 0.001 |
Cortisol ≥ 1.8 after 1 mg DST
- Entire cohort
- 12 (1.2%)
- Of these, MUO phenotype
- 11
Diagnostic performance of 1 mg DST for CS screening
- Specificity
- 99%
- Sensitivity
- 100%
Original publication
Cushing’s syndrome screening with the 1-mg dexamethasone suppression test in metabolically healthy and unhealthy obesity phenotypes. Int J Obes (Lond). Published 9 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →